Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Curosurf Articles

Chiesi opens new local business unit in China

23 June 2008

Chiesi's full year 2006 profit climbs 16%

21 May 2007

Chiesi's Curosurf cuts RDS mortality 30%

25 September 2006

Discovery submits MAA for Surfaxin

11 October 2004

Discovery files US NDA for Surfaxin

19 April 2004

Chiesi of Italy sets out expansion plans for rest of Europe

29 November 2001

Serono reports disappointing sales

31 October 2001

Net income at Switzerland's Serono jumps 42.5% as Rebif growth continues

24 July 2001

Chiesi re-acquires Curosurf rights from Serono

1 March 2001

Chiesi's 1999 sales leap 16.8% to $338.8 mill

28 February 2000

Dey and Chiesi's Curosurf OKed by FDA

25 November 1999

1998: year of expansion for Italy's Chiesi

20 April 1999

Chiesi Aims For Top 20 Place In Italian Market

5 August 1998

UK Industry Code Of Practice Report

1 September 1997

UK Industry Code of Practice Review

8 July 1996

Italy's Chiesi Does Well In Adverse Situation

15 April 1996

Chiesi Licenses Surfactant To Day Labs

25 July 1994

SERONO INTRODUCES CUROSURF

21 March 1994

GOOD PROGRESS FOR ITALY'S CHIESI GROUP

27 September 1993

ARES-SERONO NETPROFITS LEAP 51%

15 March 1993

NEW CHEMICAL ENTITIES LAUNCHED IN 1992

1 February 1993

ARES-SERONO GAINS RIGHTS TO CUROSURF

6 April 1992

ARES-SERONO GAINS RIGHTS TO CUROSURF

6 April 1992

CUROSURF LICENSING DEAL

23 March 1992

Showing 1-24 of 24 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS